DefEYE, Inc announced in a press release the publication of 2 peer-reviewed articles highlighting the use of Biovance 3L Ocular, a tri-layer decellularized basement membrane (DBM) used in ocular surgery and in ocular surface disease applications.
The first article, entitled “A Retrospective Review of Glueless, Sutureless Pterygium Excision Using Biovance Triple-Layer Decellularized Amniotic Basement Membrane Tissue,” published in Ophthalmology and Therapy and authored by Marguerite McDonald, MD,1 demonstrated outcomes of pterygium surgery, including the use of Biovance 3L Ocular.
According to DefEYE, the study reinforces the simplified, sutureless and glueless technique maintains excellent safety and efficacy. Additionally, there were no reported recurrences, pyogenic granuloma, dellen or infection. By preserving conjunctiva, reducing surgical time, and delivering effective outcomes, the glueless, sutureless technique can reduce costs of pterygium surgery and enhance outcomes for routine and high-risk cases, the company said.
The second article, entitled “Comparison of Effectiveness of Biovance Single and Triple Layer Decellularized Basement Membranes for Treatment of Ocular Surface Disease: A Retrospective Study,” published in Clinical Optometry and authored by Melanie Denton, OD,2 compared Biovance (Single Layer DBM) and Biovance 3L Ocular (Triple Layer DBM) for the treatment of ocular surface disease.
In the study, corneal healing was assessed over a 6-month period for patients receiving either Biovance or Biovance 3L Ocular, in conjunction with pressure patching. Both groups demonstrated statistically significant reductions in corneal fluorescein staining at 3 and 6 months; at 6 months, the reduction in corneal staining in the Biovance 3L Ocular group was statistically significantly greater than that observed in the Biovance group. Additionally, at both 3 and 6 months, Biovance 3L Ocular exhibited a greater magnitude and duration of corneal staining improvement compared to Biovance, thereby supporting the long-term efficacy of multi-layered DBM in the treatment of dry eye disease-related epithelial disease, the company said.
References
1. McDonald M. A retrospective review of glueless, sutureless pterygium excision using Biovance triple-layer decellularized amniotic basement membrane tissue. Ophthalmol Ther. 2026;15(2):771-780. doi:10.1007/s40123-026-01311-6
2. Denton M. Comparison of effectiveness of Biovance single and triple layer decellularized basement membranes for treatment of ocular surface disease: a retrospective study. Clin Optom (Auckl). 2026;18:1-8.